Sugi Predict

Sugi Predict / Compounds / SCHEMBL1768282

SCHEMBL1768282

SCHEMBL1768282

C[C@H](NC(Cc1ccc(-c2cc(Cl)ccc2Cl)cc1)C(=O)OCc1ccccc1)C(=O)OC(C)(C)C

nearest known ligand 0.62

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MME P08473 1/20 0.62
▸ MMEL1 Q495T6 2/20 0.48
▸ MAPT P10636 3/20 0.41
▸ NPSR1 Q6W5P4 2/20 0.41
▸ POLB P06746 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ GPR34 Q9UPC5 1/20 0.40
▸ TDP1 Q9NUW8 2/20 0.40
▸ PTPN1 P18031 1/20 0.39
▸ BCL2 P10415 1/20 0.39
▸ MCL1 Q07820 1/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ PPARA Q07869 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1793637 1.00 MME (0.62) MMEMMEL1MAPTNPSR1POLB
SCHEMBL1768280 1.00 MME (0.62) MMEMMEL1MAPTNPSR1POLB
SCHEMBL1768279 0.89 MME (0.68) MMEMMEL1MAPTNPSR1MEN1
SCHEMBL1768281 0.89 MME (0.68) MMEMMEL1MAPTNPSR1MEN1
SCHEMBL6903314 0.89 MME (0.68) MMEMMEL1MAPTNPSR1MEN1
SCHEMBL3776089 0.89 MME (0.68) MMEMMEL1MAPTNPSR1MEN1
SCHEMBL1768270 0.88 GPR34 (0.51) MMEMMEL1MAPTNPSR1GPR34
SCHEMBL1768436 0.88 GPR34 (0.51) MMEMMEL1MAPTNPSR1GPR34
SCHEMBL12520347 0.82 MME (0.43) MMEPOLBTDP1
SCHEMBL27936341 0.81 POLB (0.45) MMEPOLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2735561-B1 Substituted carbamoylmethoxyacetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2016-07-20 — — EP disclosed
EP-2640375-B1 METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY NOVARTIS AG (CH) 2016-05-18 — — EP disclosed
US-8993631-B2 Method of treating contrast-induced nephropathy NOVARTIS AG (CH) 2015-03-31 — — US disclosed
US-20140336194-A1 METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY NOVARTIS AG (CH) 2014-11-13 — — US disclosed
US-8877786-B2 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2014-11-04 — — US disclosed
EP-2735561-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors Novartis AG (CH) 2014-05-28 — — EP disclosed
EP-2501683-B1 SUBSTITUTED CARBAMOYLMETHYLAMINO ACETIC ACID DERIVATIVES AS NOVEL NEP INHIBITORS NOVARTIS AG (CH) 2014-04-23 — — EP disclosed
US-20140088165-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2014-03-27 — — US disclosed
US-8642635-B2 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2014-02-04 — — US disclosed
EP-2640375-A1 METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY Novartis AG (CH) 2013-09-25 — — EP disclosed
US-20130096168-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2013-04-18 — — US disclosed
US-8377978-B2 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2013-02-19 — — US disclosed
EP-2501683-A1 SUBSTITUTED CARBAMOYLMETHYLAMINO ACETIC ACID DERIVATIVES AS NOVEL NEP INHIBITORS Novartis AG (CH) 2012-09-26 — — EP disclosed
US-20120202862-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2012-08-09 — — US disclosed
US-8222286-B2 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2012-07-17 — — US disclosed
WO-2012065958-A1 METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY NOVARTIS AG (CH) 2012-05-24 — — WO disclosed
US-20120122844-A1 METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY NOVARTIS AG (CH) 2012-05-17 — — US disclosed
US-20110124695-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2011-05-26 — — US disclosed
WO-2011061271-A1 SUBSTITUTED CARBAMOYLMETHYLAMINO ACETIC ACID DERIVATIVES AS NOVEL NEP INHIBITORS NOVARTIS AG (CH) 2011-05-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140088165-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors MME, REN, AGTR1 MME 1/4885MMEL1 485/4885MAPT 1760/4885
US-20140336194-A1 METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY REN, SERPINB1, MME MME 3/4885MMEL1 118/4885MAPT 4543/4885
US-20130096168-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors MME, REN, AGTR1 MME 1/4885MMEL1 485/4885MAPT 1760/4885
US-20120122844-A1 METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY REN, SERPINB1, MME MME 3/4885MMEL1 118/4885MAPT 4543/4885
US-20120202862-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors MME, REN, AGTR1 MME 1/4885MMEL1 485/4885MAPT 1760/4885
US-20110124695-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors MME, REN, AGTR1 MME 1/4885MMEL1 493/4885MAPT 1754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.